Koh JWH, et al. - Researchers conducted a systematic review and meta-analysis to present the treatment efficacy and safety profile of monoclonal antibodies inhibiting IFNα or IFNAR. Researchers carried out to search Medline, Embase and ClinicalTrials.gov for biologics targeting IFNα or IFNAR in SLE up to 3 Jan 2020. The odds ratio (OR) with the Mantel Haenszel model was applied to pool analyses of biniary variables for the meta-analysis. The data demonstrate IFNAR as a therapeutic target in SLE. It was illustrated that inhibition of type I IFNs predisposes to herpes zoster and other viral infections.